S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
The single greatest medical breakthrough of all time? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:INZY

Inozyme Pharma (INZY) Stock Forecast, Price & News

$6.43
+0.06 (+0.94%)
(As of 06/2/2023 ET)
Compare
Today's Range
$6.31
$6.58
50-Day Range
$3.70
$6.74
52-Week Range
$0.99
$7.24
Volume
567,612 shs
Average Volume
1.19 million shs
Market Capitalization
$283.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Inozyme Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
148.8% Upside
$16.00 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$3.17 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.70) to ($1.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

542nd out of 983 stocks

Pharmaceutical Preparations Industry

265th out of 486 stocks


INZY stock logo

About Inozyme Pharma (NASDAQ:INZY) Stock

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Inozyme Pharma Insider Trades Send a Signal
Recap: Inozyme Pharma Q1 Earnings
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Analyst Ratings for Inozyme Pharma
Here's Why Inozyme Pharma Has My Attention
See More Headlines

INZY Price History

INZY Company Calendar

Last Earnings
3/22/2023
Today
6/03/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INZY
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+148.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-67,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.35 per share

Miscellaneous

Free Float
39,755,000
Market Cap
$283.11 million
Optionable
Not Optionable
Beta
1.08

Key Executives

  • Mr. Axel Bolte M.B.A. (Age 50)
    M.Sc., Co-Founder, Pres, CEO & Director
    Comp: $889.66k
  • Mr. Henric Bjorn Bjarke (Age 55)
    Sr. VP & COO
    Comp: $597.68k
  • Dr. Demetrios Braddock M.D.
    Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
  • Mr. Sanjay S. Subramanian M.B.A. (Age 45)
    M.S., CFO & Principal Accounting Officer
  • Dr. Soojin Kim Ph.D.
    Sr. VP & Chief Technical Operations Officer
  • Dr. Yves Sabbagh Ph.D.
    Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer
  • Mr. Stefan Riley
    Director of Investor Relations
  • Ms. Gayle Gironda
    Sr. VP & Chief People Officer
  • Dr. David Thompson M.A.
    M.S., Ph.D., Chief Devel. Officer
  • Mr. Stephen J. Di Palma M.B.A (Age 63)
    M.B.A., Consultant













INZY Stock - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INZY shares.
View INZY analyst ratings
or view top-rated stocks.

What is Inozyme Pharma's stock price forecast for 2023?

4 brokerages have issued 1 year price objectives for Inozyme Pharma's shares. Their INZY share price forecasts range from $6.00 to $23.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price.
View analysts price targets for INZY
or view top-rated stocks among Wall Street analysts.

How have INZY shares performed in 2023?

Inozyme Pharma's stock was trading at $1.05 on January 1st, 2023. Since then, INZY shares have increased by 512.4% and is now trading at $6.43.
View the best growth stocks for 2023 here
.

When is Inozyme Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our INZY earnings forecast
.

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) posted its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), Raytheon Technologies (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).

When did Inozyme Pharma IPO?

(INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Inozyme Pharma's stock symbol?

Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY."

Who are Inozyme Pharma's major shareholders?

Inozyme Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (4.05%), CHI Advisors LLC (3.07%), Affinity Asset Advisors LLC (1.72%), FMR LLC (1.61%), Samsara BioCapital LLC (1.15%) and BlackRock Inc. (1.03%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner.
View institutional ownership trends
.

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inozyme Pharma's stock price today?

One share of INZY stock can currently be purchased for approximately $6.43.

How much money does Inozyme Pharma make?

Inozyme Pharma (NASDAQ:INZY) has a market capitalization of $283.11 million. The company earns $-67,060,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How can I contact Inozyme Pharma?

The official website for the company is www.inozyme.com. The company can be reached via phone at 857-330-4340 or via email at ir@inozyme.com.

This page (NASDAQ:INZY) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -